Clinical Trial Detail

NCT ID NCT03767244
Title A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

prostate adenocarcinoma

Therapies

Apalutamide

Abiraterone + Apalutamide

Prednisone

Age Groups: adult senior

No variant requirements are available.